Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides advice to biotechnology and pharmaceutical companies as well as academic researchers and venture capital firms. Previously, he spent 14 years as a scientist at Immunex prior to its acquisition by Amgen.
The hardest task in major league sports is hitting a baseball. Those who can successfully do this even three out of every ten times over the course of a career... Read more »
A recent meeting focused on “Reinventing Biotech’s Business Model” provided an interesting window into the spectrum of approaches being used to create new biotech companies. Unfortunately, it did little... Read more »
The sequencing of the human genome didn’t immediately lead to treatments for a number of diseases, as many had hoped and a smaller number had predicted. However, the enormous drop in... Read more »
Years ago, pharma’s rep was grand,
Selling drugs throughout the land.
Many different problems mended,
Diseases treated, lives extended.
Sulfa drugs, antibiotics,
Pain-relieving strong narcotics.
A high point... Read more »
The most successful biotechs of the past quarter century have been companies that established relatively large, cutting edge research programs, such as Biogen, Immunex, and Genentech. I’ll refer to this as... Read more »
Advances in the biomedical sciences are highly dependent upon researchers having a clear understanding of the current state of knowledge. This information is primarily acquired by having access to the scientific... Read more »
Are biotech and pharma companies doing well, or falling apart at the seams? People will have differences of opinion on this, but one thing is clear: it’s all relative.
At a... Read more »
One or more notices of upcoming biopharma industry conferences arrive in my email every day. I give their agendas a quick glance before deleting them, as they’re seldom in areas I... Read more »
Developing new medicines is an amazingly difficult undertaking. The research portion alone is daunting, and for those of us who have actually attempted it, humbling. A recent article reminded me just... Read more »
If you bought a new toaster, carried it home, plugged it in, and it didn’t work, what would you do? Suppose you purchased a pineapple at the grocery store, sliced it... Read more »
If you’ve been following the drug industry at all for the past few years, you know that Big Pharma has gone alliance crazy.
It seems that every other week a new... Read more »
I frequently read comments from pundits and politicians decrying the US drug regulatory system, specifically the FDA. Many of these people, reading from the same PR playbook, will try to convince... Read more »
In the first part of this article, I detailed how pharma and biotech companies, along with the federal government, provide the majority of funding for biomedical research in the U.S.... Read more »
In case you haven’t noticed, heart disease remains a debilitating illness for millions. Cancer, despite some recent advances, has not been cured. Drug resistant strains of bacteria are spreading across the... Read more »
Biotechnology is a challenging business, with drug development timelines that are long, costly, and dependent on the approval of government regulatory agencies. The vast majority of biotechs never succeed in developing... Read more »
Cognitive dissonance is defined as “an uncomfortable feeling caused by holding conflicting ideas simultaneously.” I’m suffering from a serious case of discomfort as I try to figure out which is the... Read more »
Doctors, patients, and investors who follow the biopharmaceutical business all recognize that the industry is exceedingly complex and in the midst of change. Companies struggle daily with a multifaceted mix of... Read more »
[Updated: 11:30 am, 11/4/10] The biotech industry was a key beneficiary last spring of the new health care law. $1 billion worth of Qualifying Therapeutic Discovery Project Credits were... Read more »
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.